Over the past four years, many of us have become accustomed to a swab up the nose to test for COVID-19, using at-home rapid antigen tests or the more accurate clinic-provided PCR tests with a longer ...

The COVID-19 pandemic yielded important advances in testing for respiratory viruses, but it also exposed important unmet needs in screening to prevent the spread of infections in high-risk settings.

The COVID-19 pandemic led to many changes. Among them is universal familiarity with a molecular diagnostic technique that was largely unknown outside clinical use. The polymerase chain reaction — or ...

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented ...

These tests have very limited clinical use. The need for antibody testing would be to determine if a patient has recovered from COVID-19, and whether we could take a sample of the patient’s plasma to ...

Because of its high accuracy, laboratory-based polymerase chain reaction (PCR) testing is the gold standard for infectious disease diagnostics. However, PCR technology requires highly trained staff ...

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented ...

According to WHO, it can be difficult to clinically distinguish Ebola disease from other infectious diseases such as malaria, typhoid fever, shigellosis, meningitis and other viral haemorrhagic fevers ...

Over the past four years, many of us have become accustomed to a swab up the nose to test for COVID-19, using at-home rapid antigen tests or the more accurate clinic-provided PCR tests with a longer ...